7Shirasaka T, Shimamoto Y, Ohshima H, et al. Development of a novel form of an oral 5-fluorouracil derivative ( S- 1 ) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators [ J ]. Anticancer Drugs, 1996, 7 : 548.
8Takeharu Y, Shigemi M, Satoshi T, et al. Safety evaluation of oral fluoropyrimidine S-1 for short-and long-term delivery in advanced gastric cancer: Analysis of 3 758 patients [J]. Cancer Chemother Pharmaeol, 2008, 61:335.
9Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1 , a novel oral derivative of 5-fluorouracil, in advanced gastric cancer [J]. Oncology, 2000, 58 : 191.
10Sakata Y, Ohtsu A, Horikoshi N, et al. Late Phase Ⅱ study of novel oral fluoropyrimidine anticancer drug S-1 ( 1M tegafur-0. 4M otastat potassium) in advanced gastric cancer patients [J]. EUR J Cancer, 1998, 34 : 1715.
